In China, Left Ventricular Assist Devices (LVADs) are increasingly adopted to improve the quality of life for patients with end-stage heart failure. This study aims to systematically present the clinical data and outcomes of LVAD implantations performed at Anhui Chest Hospital.
Methods
We retrospectively analyzed 28 consecutive patients who underwent LVAD implantation from October 2024 to July 2025. Preoperative baselines were compared with 3-months postoperative outcomes, including Left Ventricular End-Diastolic Diameter (LVEDD), Ejection Fraction (LVEF), NYHA functional class, and 6-Minute Walk Distance (6MWD). Adverse events were recorded.
Results
All 28 patients (20 males; mean age 59.7 ± 12.3 years) successfully underwent the procedure. The postoperative ICU stay was 10 ± 5.9 days. Complications within 90 days included hemorrhagic stroke (7%), malignant arrhythmia (3.5%), renal failure (3.5%), poor wound healing (3.5%), and one death (3.5%). No device malfunctions occurred. At 3 months, LVEDD significantly decreased (61.3 ± 5.8 vs 75.2 ± 9.4 mm), while LVEF (34.8 ± 9.8% vs 22.7 ± 5.6%) and 6MWD (356.1 ± 159.4 m vs 85 ± 49.6 m) significantly increased (all p < 0.01). All surviving patients improved to NYHA class I–II.
Conclusion
Preliminary results indicate that the application of Chinese LVADs demonstrates favorable clinical efficacy and acceptable safety profiles, serving as effective therapeutic strategies for advanced heart failure.
HaoGWangXChenZ, et al.Prevalence of heart failure and left ventricular dysfunction in China: the China hypertension survey, 2012-2015. Eur J Heart Fail2019; 21: 1329–1337.
2.
GaoXXuZChenC, et al.Full-scale numerical simulation of hemodynamics based on left ventricular assist device. Front Physiol2023; 14: 1192610.
3.
HavakukOHochstadtASadonS, et al.Successful conservative management of left ventricular assist device candidates. ESC Heart Fail2023; 10: 601–615.
4.
ThihaSZaidiARZRobertCA, et al.A rising hope of an artificial heart: left ventricular assisted device - outcome, convenience, and quality of life. Cureus2019; 11: e5617.
5.
McDonaghTAMetraMAdamoM, et al.2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J2021; 42(36): 3599–3726.
6.
MehraMRGoldsteinDJClevelandJC, et al.Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized clinical trial. JAMA2022; 328: 1233–1242.
7.
GosevIWoodKAyersB, et al.Implantation of a fully magnetically levitated left ventricular assist device using a sternal-sparing surgical technique. J Heart Lung Transplant2020; 39: 37–44.
8.
McGeeEJDanterMStrueberM, et al.Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: the LATERAL clinical trial. J Heart Lung Transplant2019; 38: 344–351.
9.
RiebandtJSchloglhoferTMoayedifarR, et al.Less invasive left ventricular assist device implantation is safe and reduces intraoperative blood product use: a propensity score analysis VAD implantation techniques and blood product use. ASAIO J2021; 67: 47–52.
10.
GradyKLNaftelDStevensonL, et al.Overall quality of life improves to similar levels after mechanical circulatory support regardless of severity of heart failure before implantation. J Heart Lung Transplant2014; 33: 412–421.
11.
YoshiokaDTakayamaHGaranAR, et al.Bridge to durable left ventricular assist device for refractory cardiogenic shock. J Thorac Cardiovasc Surg2017; 153: 752–762.
12.
CaraballoCDeFilippisEMNakagawaS, et al.Clinical outcomes after left ventricular assist device implantation in older adults: an INTERMACS analysis. JACC Heart Fail2019; 7: 1069–1078.
13.
IvanovBDjordjevicISabashnikovA, et al.Impact of ischaemic and dilated cardiomyopathy on short-term and long-term survival after ventricular assist device implantation: a single-centre experience. Heart Lung Circ2022; 31: 383–389.
14.
KilicAChenCWGaffeyAC, et al.Preoperative renal dysfunction does not affect outcomes of left ventricular assist device implantation. J Thorac Cardiovasc Surg2018; 156: 1093–1101.
15.
ArgenzianoMChoudhriAFMoazamiN, et al.Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg1998; 65: 340–345.
16.
MikusEStepanenkoAKrabatschT, et al.Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardio Thorac Surg2011; 40: 971–977.
17.
VestARWongWWCheryJ, et al.Skeletal muscle mass recovery early after left ventricular assist device implantation in patients with advanced systolic heart failure. Circ Heart Fail2022; 15: e009012.
18.
Mendiola PlaMChiangYNicoaraA, et al.Surgical treatment of tricuspid valve regurgitation in patients undergoing left ventricular assist device implantation: interim analysis of the TVVAD trial. J Thorac Cardiovasc Surg2024; 167: 1810–1820.
19.
ShahSWangCCamachoGA, et al.Long-term outcomes of tricuspid valve repair or replacement in patients with a continuous-flow left ventricular assist device. J Thorac Cardiovasc Surg2025; 170: 1678–1686.
20.
PiacentinoV3rdTroupesCDGanapathiAM, et al.Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation. Ann Thorac Surg2011; 92: 1414–1418.
21.
AndoMOnoM. Concomitant or late aortic valve intervention and its efficacy for aortic insufficiency associated with continuous-flow left ventricular assist device implantation. Front Cardiovasc Med2022; 9: 1029984.
22.
JohnRKanwarMKClevelandJCJr, et al.Concurrent valvular procedures during left ventricular assist device implantation and outcomes: a comprehensive analysis of the multicenter study of MagLev technology in patients undergoing mechanical circulatory support therapy with HeartMate 3 trial portfolio. J Heart Lung Transplant2022; 41: 647–658.
23.
AdamopoulosSBoniosMBen GalT, et al.Right heart failure with left ventricular assist devices: preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the heart failure association (HFA) of the ESC. Eur J Heart Fail2024; 26: 2304–2322.
24.
KanelidisAJGozdeckiLBelkinMN, et al.Mitigating post-operative right ventricular dysfunction after left ventricular assist device: the RV protection study. J Card Fail2025; 32(1): 46–57. DOI: 10.1016/j.cardfail.2025.01.017, Epub ahead of print 13.
25.
AdamopoulosSBoniosMBen GalT, et al.Right heart failure with left ventricular assist devices: preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the heart failure association (HFA) of the ESC. Eur J Heart Fail2024; 26: 2304–2322.
26.
TakedaKNakaYYangJA, et al.Outcome of unplanned right ventricular assist device support for severe right heart failure after implantable left ventricular assist device insertion. J Heart Lung Transplant2014; 33: 141–148.
27.
TrachtenbergBCowgerJJenningsDL, et al.HFSA expert consensus statement on the medical management of patients on durable mechanical circulatory support. J Card Fail2023; 29: 479–502.
28.
KöhlerAKKörperichHMorshuisM, et al.Pre-operative risk factors for driveline infection in left ventricular-assist device patients. ESC Heart Fail2022; 9: 3995–4002.
29.
BediMKormosRWinowichS, et al.Ventricular arrhythmias during left ventricular assist device support. Am J Cardiol2007; 99: 1151–1153.
